Business, energy, technology, markets and global industry news from Business News Today

ABS-1230

PharmaDeviceNews ABS-1230
Infographic highlighting Setara’s $90 million financing to advance STAR-0871 for Charcot-Marie-Tooth disease type 2C (CMT2C) and overactive bladder, featuring neurological and bladder illustrations and the continuation of Actio’s development pipeline following the Jazz acquisition.
Pharma & Biotech

Setara Biosciences raises $90m to advance STAR-0871 for CMT2C and overactive bladder after Jazz acquisition

Setara raises $90m to advance STAR-0871 for CMT2C and overactive bladder, carrying forward Actio’s pipeline after the Jazz acquisition.

Read More
Representative image: A pediatric neurology research setting highlights the clinical and regulatory stakes behind Actio Biosciences’ KYRON trial of ABS-1230 for KCNT1-related epilepsy, as precision medicine developers seek new treatment pathways for ultra-rare genetic seizure disorders.
Pharma & Biotech

Could Actio’s KCNT1 epilepsy drug become an ultra-rare disease test case for the FDA?

Ultra-rare epilepsy has few paths forward. Actio’s ABS-1230 now tests whether precision genetics can reshape FDA evidence standards.

Read More